

Table of contents

Table of contents	i
List of tables	v
List of figures	vii
List of abbreviations	ix
Summary	xi
Zusammenfassung	xv
Résumé	xxi
Acknowledgements	xxix
1. Introduction	1
1.1. Schistosomiasis: biology and life cycle	1
1.2. Schistosomiasis distribution	4
1.2.1. Schistosomiasis in the world	4
1.2.2. Schistosomiasis in Niger	5
1.3. Morbidity due to schistosomiasis	6
1.3.1. Urogenital schistosomiasis	7
1.3.2. Intestinal schistosomiasis	8
1.4. Diagnostic of schistosomiasis	9
1.4.1. Clinical diagnostic	9
1.4.2. Parasitological diagnostics	9
1.4.3. Immunological diagnosis	10
1.4.4. Other diagnostic methods	10
1.4.5. Community diagnostic	11
1.5. Schistosomiasis control	13
1.5.1. Preventive chemotherapy	13
1.5.2. The move towards elimination	15
1.6. References	15
2. Goals and objectives	33
2.1. Aim of the study	33
2.2. Specific objectives	33
3. Present and future schistosomiasis control activities with support from the 'Schistosomiasis Control Initiative' in West Africa	35
3.1. Summary	36
3.2. Introduction	37
3.3. National schistosomiasis control programmes in Burkina Faso, Mali and Niger	38
3.3.1. Distribution of the disease	38
3.3.2. Objectives, targets and strategies of control programmes	38
3.4. Mass treatment and its impact	38
3.5. Maintaining the benefits of mass treatment	43
3.5.1. The continuation of the treatment campaigns	43
3.5.2. Villages targeted for control	44
3.5.3. Additional control strategies	45
3.5.4. Can we consider transmission control?	45

3.6. Future: Integration of the programmes and the control of neglected tropical diseases	46
3.7. Conclusion.....	46
3.8. Acknowledgements	47
3.9. References	48
4. Schistosomiasis in infants and preschool-aged children: infection in a single <i>Schistosoma haematobium</i> and a mixed <i>S. haematobium</i>-<i>S. mansoni</i> foci of Niger..	53
4.1. Abstract	54
4.2. Introduction.....	55
4.3. Materials and methods	56
4.3.1. Study area.....	56
4.3.2. Ethical consideration and treatment.....	57
4.3.3. Questionnaire survey	58
4.3.4. Parasitological survey	58
4.3.5. Statistical analysis	59
4.4. Results	59
4.4.1. Characteristics of study population	59
4.4.2. Infection with <i>S. haematobium</i>	60
4.4.3. Infection with <i>S. mansoni</i>	61
4.4.4. Co-infection with <i>S. haematobium</i> and <i>S. mansoni</i>	62
4.4.5. Risks factors for early childhood schistosome infections	62
4.5. Discussion	65
4.6. Acknowledgements.....	70
4.7. References.....	71
5. Efficacy and safety of two closely spaced doses of praziquantel against <i>Schistosoma haematobium</i> and <i>S. mansoni</i> and re-infection patterns in school-aged children in Niger.....	75
5.1. Abstract	76
5.2. Introduction	77
5.3. Materials and methods	79
5.3.1. Study area.....	79
5.3.2. Study design	80
5.3.3. Ethics statement and operational considerations.....	80
5.3.4. Field and laboratory procedures.....	81
5.3.5. Treatment and monitoring of adverse events	82
5.3.6. Statistical analysis	82
5.4. Results	83
5.4.1. Study profile and compliance.....	83
5.4.2. Safety of PZQ.....	86
5.4.3. Re-infection patterns	93
5.5. Discussion	94
5.6. Conflicts of interest	98
5.7. Authors' contributions	98
5.8. Acknowledgements	99
5.9. References	99
6. Safety and efficacy of praziquantel syrup (Epiquantel®) against <i>Schistosoma haematobium</i> and <i>Schistosoma mansoni</i> in preschool-aged children in Niger.....	107
6.1. Abstract	108
6.2. Introduction	110

6.3. Materials and methods	112
6.3.1. Study design and investigational drug	112
6.3.2. Study sites	113
6.3.3. Study population	114
6.3.4. Procedures	114
6.3.5. Ethical consideration	117
6.3.6. Statistical analysis	118
6.4. Results	118
6.4.1. Characteristics of the study population	118
6.4.2. Safety of praziquantel syrup	119
6.4.3. Efficacy of praziquantel syrup against <i>S. haematobium</i>	120
6.4.4. Efficacy of praziquantel syrup against <i>S. mansoni</i>	124
6.5. Discussion	126
6.6. Conflicts of interest	131
6.7. Authors' contributions	131
6.8. Acknowledgements	131
6.9. References	132
7. Schistosomiasis and Soil-Transmitted Helminth control in Niger: cost-effectiveness of school-based and community distributed mass drug administration	137
7.1. Abstract	138
7.2. Author Summary	139
7.3. Introduction	140
7.4. Description of the programme for mass drug administration in Niger	140
7.5. Methods	144
7.5.1. Determination of the economic cost of treatment	145
7.5.2. School based and community delivery system cost calculation	147
7.5.3. Cost effectiveness analysis	147
7.6. Results	148
7.6.1. Total economic costs of treatment	148
7.6.2. Cost of community based and school based delivery systems	153
7.6.3. Cost effectiveness of treatment	155
7.7. Discussion	156
7.8. Conclusion	161
7.9. Acknowledgements	161
7.10. References	162
7.11. Supporting information	165
8. Discussion and conclusion	169
8.1. Challenges for sustainable schistosomiasis control in sub-Saharan Africa	169
8.2. Maintaining the reduction of morbidity achieved	171
8.3. Monitoring the efficacy of PZQ	172
8.4. Including preschool-aged children in PCT	173
9. Research needs	175
10. References	177
11. Curriculum vitae	183